VP Clinical Development @ Miist Tx | Analytical Thinker | Operationally & Commercially Balanced | Connector
This week is world glaucoma week. Glaucoma is characterised by the degeneration of retinal ganglion cells and retinal nerve fiber layers that result in changes in the optical nerve head, which end up affecting vision and can progress to full visual loss. NeuroScientific Biopharmaceuticals Ltd is focused on developing #EmtinB as a much needed neuroprotective and possibly neuroregenerative product for #glaucoma that will hopefully prevent, slow down and possibly reverse vision loss in glaucoma patients, which is expected to affect as many as 112 million people worldwide by 2040.